Literature DB >> 27913089

A combined one-stage surgical approach of orbital tumor debulking, lid reconstruction, and ptosis repair in children with orbitotemporal neurofibromatosis.

Shay Keren1, Gad Dotan2, Ran Ben-Cnaan2, Leah Leibovitch3, Igal Leibovitch2.   

Abstract

BACKGROUND AND AIM: To describe a series of children with neurofibromatosis type 1 (NF1) and a plexiform neurofibroma of the orbit with ptosis who underwent a combined one-stage surgery for tumor debulking, lid reconstruction, and ptosis repair.
METHODS: A retrospective review of 6 cases of combined one-step surgeries for orbital plexiform neurofibroma with ptosis.
RESULTS: The study included 6 children (4 boys, mean age 3.4 years). Follow-up time was at least 9 months. All children had unilateral orbitofacial plexiform. All children underwent a combined one-stage surgery performed by a single surgeon for tumor debulking, lid reconstruction, and ptosis repair. There was significant improvement in upper lid height and lid contour postoperatively in all the patients. One patient had early recurrence and underwent another two surgeries in the following years.
CONCLUSION: A combined surgical approach for orbital involvement in NF1 results in favorable immediate results, though late recurrence may require additional surgical interventions in the future.
Copyright © 2016 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Neurofibromatosis; Orbit; Plexiform; Ptosis; Surgery

Mesh:

Year:  2016        PMID: 27913089     DOI: 10.1016/j.bjps.2016.10.015

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  1 in total

1.  Trametinib for orbital plexiform neurofibromas in young children with neurofibromatosis type 1.

Authors:  Helen Toledano; Gad Dotan; Rivka Friedland; Rony Cohen; Iftach Yassur; Hagit Toledano-Alhadef; Shlomi Constantini; Mika Shapira Rootman
Journal:  Childs Nerv Syst       Date:  2021-03-22       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.